Gilead’s Ulcerative Colitis Pill Achieves Remission in Phase 2 Trial
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Gilead Sciences’ oral drug emvistegrast produced a 23% placebo-adjusted clinical remission rate in patients with moderate to severe ulcerative colitis. The Phase 2 trial tested a daily 200 mg dose for 12 weeks, delivering a statistically significant result above analysts’ expectations.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu